Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 12569 entries
Sorted by: Best Match Show Resources per page
[No title available]

Frontiers in pharmacology

Chen R, Zheng X, Hu P.
PMID: 28512430
Front Pharmacol. 2017 May 02;8:239. doi: 10.3389/fphar.2017.00239. eCollection 2017.

No abstract available.

Cite
Chen R, Zheng X, Hu P. . Front Pharmacol. 2017;8:239doi: 10.3389/fphar.2017.00239.
Chen, R., Zheng, X., & Hu, P. (2017). . Frontiers in pharmacology, 8239. https://doi.org/10.3389/fphar.2017.00239
Chen, Rui, et al. "." Frontiers in pharmacology vol. 8 (2017): 239. doi: https://doi.org/10.3389/fphar.2017.00239
Chen R, Zheng X, Hu P. . Front Pharmacol. 2017 May 02;8:239. doi: 10.3389/fphar.2017.00239. eCollection 2017. PMID: 28512430; PMCID: PMC5411458.
Copy Download .nbib Format: NLM
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.

Frontiers in pharmacology

Liberti L, Bujar M, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H.
PMID: 28420989
Front Pharmacol. 2017 Apr 03;8:161. doi: 10.3389/fphar.2017.00161. eCollection 2017.

The US Food and Drug Administration (FDA) has four facilitated regulatory pathways (FRPs): Fast Track (FT), Breakthrough Therapy (BTD), Priority Review (PR), and Accelerated Approval (AA). Only PR specifies an expedited review timeline (6 months). We sought to determine...

Cite
Liberti L, Bujar M, Breckenridge A, et al. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Front Pharmacol. 2017;8:161doi: 10.3389/fphar.2017.00161.
Liberti, L., Bujar, M., Breckenridge, A., Hoekman, J., McAuslane, N., Stolk, P., & Leufkens, H. (2017). FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Frontiers in pharmacology, 8161. https://doi.org/10.3389/fphar.2017.00161
Liberti, Lawrence, et al. "FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines." Frontiers in pharmacology vol. 8 (2017): 161. doi: https://doi.org/10.3389/fphar.2017.00161
Liberti L, Bujar M, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines. Front Pharmacol. 2017 Apr 03;8:161. doi: 10.3389/fphar.2017.00161. eCollection 2017. PMID: 28420989; PMCID: PMC5376616.
Copy Download .nbib Format: NLM
Heme as a Target for Therapeutic Interventions.

Frontiers in pharmacology

Immenschuh S, Vijayan V, Janciauskiene S, Gueler F.
PMID: 28420988
Front Pharmacol. 2017 Apr 04;8:146. doi: 10.3389/fphar.2017.00146. eCollection 2017.

Heme is a complex of iron and the tetrapyrrole protoporphyrin IX with essential functions in aerobic organisms. Heme is the prosthetic group of hemoproteins such as hemoglobin and myoglobin, which are crucial for reversible oxygen binding and transport. By...

Cite
Immenschuh S, Vijayan V, Janciauskiene S, et al. Heme as a Target for Therapeutic Interventions. Front Pharmacol. 2017;8:146doi: 10.3389/fphar.2017.00146.
Immenschuh, S., Vijayan, V., Janciauskiene, S., & Gueler, F. (2017). Heme as a Target for Therapeutic Interventions. Frontiers in pharmacology, 8146. https://doi.org/10.3389/fphar.2017.00146
Immenschuh, Stephan, et al. "Heme as a Target for Therapeutic Interventions." Frontiers in pharmacology vol. 8 (2017): 146. doi: https://doi.org/10.3389/fphar.2017.00146
Immenschuh S, Vijayan V, Janciauskiene S, Gueler F. Heme as a Target for Therapeutic Interventions. Front Pharmacol. 2017 Apr 04;8:146. doi: 10.3389/fphar.2017.00146. eCollection 2017. PMID: 28420988; PMCID: PMC5378770.
Copy Download .nbib Format: NLM
Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats.

Frontiers in pharmacology

Sun L, Yuan Q, Xu T, Yao L, Feng J, Ma J, Wang L, Lu C, Wang D.
PMID: 28860994
Front Pharmacol. 2017 Aug 15;8:545. doi: 10.3389/fphar.2017.00545. eCollection 2017.

Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment. However, the underlying mechanism involved in the renoprotection of pioglitazone has not been fully revealed....

Cite
Sun L, Yuan Q, Xu T, et al. Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats. Front Pharmacol. 2017;8:545doi: 10.3389/fphar.2017.00545.
Sun, L., Yuan, Q., Xu, T., Yao, L., Feng, J., Ma, J., Wang, L., Lu, C., & Wang, D. (2017). Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats. Frontiers in pharmacology, 8545. https://doi.org/10.3389/fphar.2017.00545
Sun, Li, et al. "Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats." Frontiers in pharmacology vol. 8 (2017): 545. doi: https://doi.org/10.3389/fphar.2017.00545
Sun L, Yuan Q, Xu T, Yao L, Feng J, Ma J, Wang L, Lu C, Wang D. Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats. Front Pharmacol. 2017 Aug 15;8:545. doi: 10.3389/fphar.2017.00545. eCollection 2017. PMID: 28860994; PMCID: PMC5559534.
Copy Download .nbib Format: NLM
Corrigendum: Antioxidant Effect of Fructus Ligustri Lucidi Aqueous Extract in Ovariectomized Rats Is Mediated through Nox4-ROS-NF-κB Pathway.

Frontiers in pharmacology

Wang L, Ma R, Guo Y, Sun J, Liu H, Zhu R, Liu C, Li J, Li L, Chen B, Sun L, Tang J, Zhao D, Mo F, Niu J, Jiang G, Fu M, Brömme D, Zhang D, Gao S.
PMID: 28860995
Front Pharmacol. 2017 Aug 25;8:590. doi: 10.3389/fphar.2017.00590. eCollection 2017.

[This corrects the article on p. 266 in vol. 8, PMID: 28588482.].

Cite
Wang L, Ma R, Guo Y, et al. Corrigendum: Antioxidant Effect of Fructus Ligustri Lucidi Aqueous Extract in Ovariectomized Rats Is Mediated through Nox4-ROS-NF-κB Pathway. Front Pharmacol. 2017;8:590doi: 10.3389/fphar.2017.00590.
Wang, L., Ma, R., Guo, Y., Sun, J., Liu, H., Zhu, R., Liu, C., Li, J., Li, L., Chen, B., Sun, L., Tang, J., Zhao, D., Mo, F., Niu, J., Jiang, G., Fu, M., Brömme, D., Zhang, D., & Gao, S. (2017). Corrigendum: Antioxidant Effect of Fructus Ligustri Lucidi Aqueous Extract in Ovariectomized Rats Is Mediated through Nox4-ROS-NF-κB Pathway. Frontiers in pharmacology, 8590. https://doi.org/10.3389/fphar.2017.00590
Wang, Lili, et al. "Corrigendum: Antioxidant Effect of Fructus Ligustri Lucidi Aqueous Extract in Ovariectomized Rats Is Mediated through Nox4-ROS-NF-κB Pathway." Frontiers in pharmacology vol. 8 (2017): 590. doi: https://doi.org/10.3389/fphar.2017.00590
Wang L, Ma R, Guo Y, Sun J, Liu H, Zhu R, Liu C, Li J, Li L, Chen B, Sun L, Tang J, Zhao D, Mo F, Niu J, Jiang G, Fu M, Brömme D, Zhang D, Gao S. Corrigendum: Antioxidant Effect of Fructus Ligustri Lucidi Aqueous Extract in Ovariectomized Rats Is Mediated through Nox4-ROS-NF-κB Pathway. Front Pharmacol. 2017 Aug 25;8:590. doi: 10.3389/fphar.2017.00590. eCollection 2017. PMID: 28860995; PMCID: PMC5574906.
Copy Download .nbib Format: NLM
HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis.

Frontiers in pharmacology

Wang X, Cui DN, Dai XM, Wang J, Zhang W, Zhang ZJ, Xu FG.
PMID: 28424615
Front Pharmacol. 2017 Mar 30;8:156. doi: 10.3389/fphar.2017.00156. eCollection 2017.

Irinotecan (CPT-11) is a potent chemotherapeutic agent, however, its clinical usage is often limited by the induction of severe gastrointestinal (GI) toxicity, especially late-onset diarrhea. HuangQin Decoction (HQD), commonly used for the treatment of GI ailments, has been proved...

Cite
Wang X, Cui DN, Dai XM, et al. HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Front Pharmacol. 2017;8:156doi: 10.3389/fphar.2017.00156.
Wang, X., Cui, D. N., Dai, X. M., Wang, J., Zhang, W., Zhang, Z. J., & Xu, F. G. (2017). HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Frontiers in pharmacology, 8156. https://doi.org/10.3389/fphar.2017.00156
Wang, Xu, et al. "HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis." Frontiers in pharmacology vol. 8 (2017): 156. doi: https://doi.org/10.3389/fphar.2017.00156
Wang X, Cui DN, Dai XM, Wang J, Zhang W, Zhang ZJ, Xu FG. HuangQin Decoction Attenuates CPT-11-Induced Gastrointestinal Toxicity by Regulating Bile Acids Metabolism Homeostasis. Front Pharmacol. 2017 Mar 30;8:156. doi: 10.3389/fphar.2017.00156. eCollection 2017. PMID: 28424615; PMCID: PMC5371663.
Copy Download .nbib Format: NLM
Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart.

Frontiers in pharmacology

Nistri S, Sassoli C, Bani D.
PMID: 28424623
Front Pharmacol. 2017 Apr 05;8:187. doi: 10.3389/fphar.2017.00187. eCollection 2017.

Notch signaling is a major intercellular coordination mechanism highly conserved throughout evolution. In vertebrates, Notch signaling is physiologically involved in embryo development, including mesenchymal cell commitment, formation of heart tissues and angiogenesis. In post-natal life, Notch signaling is maintained...

Cite
Nistri S, Sassoli C, Bani D. Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart. Front Pharmacol. 2017;8:187doi: 10.3389/fphar.2017.00187.
Nistri, S., Sassoli, C., & Bani, D. (2017). Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart. Frontiers in pharmacology, 8187. https://doi.org/10.3389/fphar.2017.00187
Nistri, Silvia, et al. "Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart." Frontiers in pharmacology vol. 8 (2017): 187. doi: https://doi.org/10.3389/fphar.2017.00187
Nistri S, Sassoli C, Bani D. Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart. Front Pharmacol. 2017 Apr 05;8:187. doi: 10.3389/fphar.2017.00187. eCollection 2017. PMID: 28424623; PMCID: PMC5381357.
Copy Download .nbib Format: NLM
Commentary: A BK (Slo1) channel journey from molecule to physiology.

Frontiers in pharmacology

Tricarico D, Mele A.
PMID: 28424624
Front Pharmacol. 2017 Apr 05;8:188. doi: 10.3389/fphar.2017.00188. eCollection 2017.

No abstract available.

Cite
Tricarico D, Mele A. Commentary: A BK (Slo1) channel journey from molecule to physiology. Front Pharmacol. 2017;8:188doi: 10.3389/fphar.2017.00188.
Tricarico, D., & Mele, A. (2017). Commentary: A BK (Slo1) channel journey from molecule to physiology. Frontiers in pharmacology, 8188. https://doi.org/10.3389/fphar.2017.00188
Tricarico, Domenico, and Mele, Antonietta. "Commentary: A BK (Slo1) channel journey from molecule to physiology." Frontiers in pharmacology vol. 8 (2017): 188. doi: https://doi.org/10.3389/fphar.2017.00188
Tricarico D, Mele A. Commentary: A BK (Slo1) channel journey from molecule to physiology. Front Pharmacol. 2017 Apr 05;8:188. doi: 10.3389/fphar.2017.00188. eCollection 2017. PMID: 28424624; PMCID: PMC5380717.
Copy Download .nbib Format: NLM
Protective Effects of Otophylloside N on Pentylenetetrazol-Induced Neuronal Injury In vitro and In vivo.

Frontiers in pharmacology

Sheng F, Chen M, Tan Y, Xiang C, Zhang M, Li B, Su H, He C, Wan J, Li P.
PMID: 27504096
Front Pharmacol. 2016 Jul 25;7:224. doi: 10.3389/fphar.2016.00224. eCollection 2016.

Approximately 30% of epileptic patients worldwide are medically unable to control their seizures. In addition, repeated epileptic seizures generally lead to neural damage. Pentylenetetrazol (PTZ) is a clinical circulatory and respiratory stimulant that is experimentally used to mimic epileptic...

Cite
Sheng F, Chen M, Tan Y, et al. Protective Effects of Otophylloside N on Pentylenetetrazol-Induced Neuronal Injury In vitro and In vivo. Front Pharmacol. 2016;7:224doi: 10.3389/fphar.2016.00224.
Sheng, F., Chen, M., Tan, Y., Xiang, C., Zhang, M., Li, B., Su, H., He, C., Wan, J., & Li, P. (2016). Protective Effects of Otophylloside N on Pentylenetetrazol-Induced Neuronal Injury In vitro and In vivo. Frontiers in pharmacology, 7224. https://doi.org/10.3389/fphar.2016.00224
Sheng, Feiya, et al. "Protective Effects of Otophylloside N on Pentylenetetrazol-Induced Neuronal Injury In vitro and In vivo." Frontiers in pharmacology vol. 7 (2016): 224. doi: https://doi.org/10.3389/fphar.2016.00224
Sheng F, Chen M, Tan Y, Xiang C, Zhang M, Li B, Su H, He C, Wan J, Li P. Protective Effects of Otophylloside N on Pentylenetetrazol-Induced Neuronal Injury In vitro and In vivo. Front Pharmacol. 2016 Jul 25;7:224. doi: 10.3389/fphar.2016.00224. eCollection 2016. PMID: 27504096; PMCID: PMC4959150.
Copy Download .nbib Format: NLM
Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Frontiers in pharmacology

Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D.
PMID: 27242528
Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016.

In the human genome more than 400 genes encode ion channels, which are transmembrane proteins mediating ion fluxes across membranes. Being expressed in all cell types, they are involved in almost all physiological processes, including sense perception, neurotransmission, muscle...

Cite
Imbrici P, Liantonio A, Camerino GM, et al. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016;7:121doi: 10.3389/fphar.2016.00121.
Imbrici, P., Liantonio, A., Camerino, G. M., De Bellis, M., Camerino, C., Mele, A., Giustino, A., Pierno, S., De Luca, A., Tricarico, D., Desaphy, J. F., & Conte, D. (2016). Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Frontiers in pharmacology, 7121. https://doi.org/10.3389/fphar.2016.00121
Imbrici, Paola, et al. "Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery." Frontiers in pharmacology vol. 7 (2016): 121. doi: https://doi.org/10.3389/fphar.2016.00121
Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol. 2016 May 10;7:121. doi: 10.3389/fphar.2016.00121. eCollection 2016. PMID: 27242528; PMCID: PMC4861771.
Copy Download .nbib Format: NLM
Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat.

Frontiers in pharmacology

Vera G, López-Pérez AE, Uranga JA, Girón R, Martín-Fontelles MI, Abalo R.
PMID: 28220074
Front Pharmacol. 2017 Feb 06;8:37. doi: 10.3389/fphar.2017.00037. eCollection 2017.

No abstract available.

Cite
Vera G, López-Pérez AE, Uranga JA, et al. Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat. Front Pharmacol. 2017;8:37doi: 10.3389/fphar.2017.00037.
Vera, G., López-Pérez, A. E., Uranga, J. A., Girón, R., Martín-Fontelles, M. I., & Abalo, R. (2017). Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat. Frontiers in pharmacology, 837. https://doi.org/10.3389/fphar.2017.00037
Vera, Gema, et al. "Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat." Frontiers in pharmacology vol. 8 (2017): 37. doi: https://doi.org/10.3389/fphar.2017.00037
Vera G, López-Pérez AE, Uranga JA, Girón R, Martín-Fontelles MI, Abalo R. Involvement of Cannabinoid Signaling in Vincristine-Induced Gastrointestinal Dysmotility in the Rat. Front Pharmacol. 2017 Feb 06;8:37. doi: 10.3389/fphar.2017.00037. eCollection 2017. PMID: 28220074; PMCID: PMC5292571.
Copy Download .nbib Format: NLM
Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets.

Frontiers in pharmacology

Karagueuzian HS, Pezhouman A, Angelini M, Olcese R.
PMID: 28220073
Front Pharmacol. 2017 Feb 06;8:36. doi: 10.3389/fphar.2017.00036. eCollection 2017.

While recent advances clarified the molecular and cellular modes of action of antiarrhythmic drugs (AADs), their link to suppression of dynamical arrhythmia mechanisms remains only partially understood. The current classifications of AADs (Classes I, III, and IV) rely on...

Cite
Karagueuzian HS, Pezhouman A, Angelini M, et al. Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets. Front Pharmacol. 2017;8:36doi: 10.3389/fphar.2017.00036.
Karagueuzian, H. S., Pezhouman, A., Angelini, M., & Olcese, R. (2017). Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets. Frontiers in pharmacology, 836. https://doi.org/10.3389/fphar.2017.00036
Karagueuzian, Hrayr S, et al. "Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets." Frontiers in pharmacology vol. 8 (2017): 36. doi: https://doi.org/10.3389/fphar.2017.00036
Karagueuzian HS, Pezhouman A, Angelini M, Olcese R. Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets. Front Pharmacol. 2017 Feb 06;8:36. doi: 10.3389/fphar.2017.00036. eCollection 2017. PMID: 28220073; PMCID: PMC5292429.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 12569 entries